Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Candida Infection Testing Market During the Forecast Period, and Why?

The market size for testing of candida infection has seen a robust expansion in the past years. Predictions suggest that it will rise from $15.69 billion in 2024 to $16.72 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.6%. This growth observed in the historical period is due to various factors including a surge in occurrences of candida infections, enhanced awareness and diagnostics, development of healthcare infrastructure, an increase in hospital-acquired infections, and a rise in research funding.

There is an anticipated robust growth for the market size of candida infection testing in the upcoming years. The market is projected to expand to $21.29 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.2%. This predicted surge in the forecasted period is due to factors such as the discovery of new candida strains, increasing awareness of fungal infections, growth in healthcare accessibility, an ageing population and enhanced awareness of and emphasis on preventive healthcare. Key trends to look out for in the forecasted period encompass improvements in molecular diagnostics, incorporation of digital health technologies, artificial intelligence (AI) integration, incorporation of machine learning, and the move towards personalized medicine.

Which Primary Drivers Are Supporting the Continued Expansion of the Candida Infection Testing Market?

The expected growth of the candida infection testing market can be largely attributed to the escalating occurrence of yeast infections. Yeast infections are defined as fungal infections arising due to an excess of candida, often affecting parts like the mouth, genitals, and skin, typically leading to symptoms such as itchiness, redness, and discomfort. The prime cause of yeast infections is the proliferation of the fungus candida, usually a result of the body’s natural bacteria imbalance, compromised immune systems, or hormonal shifts. Candida infection tests are crucial in yeast infection cases for precisely diagnosing the overgrowth of candida, thereby enabling healthcare professionals to confirm the infection and prescribe the suitable treatment. For instance, as per a GOV.UK report in September 2023, the yeast-induced bloodstream infections (BSI) rate in England for 2022 stood at 4.0 per 100,000 population, signifying a 4% hike as compared to 2021. Therefore, the increasing occurrence of yeast infections will fuel the candida infection testing market’s growth.

Explore Comprehensive Insights Into The Global Candida Infection Testing Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19356&type=smp

Which Companies Are Poised to Shape the Future of the Candida Infection Testing Market?

Major companies operating in the candida infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, Private MD Labs LLC

What Are the Latest Innovations and Trends Influencing the Candida Infection Testing Market?

Leading firms in the candida infection testing market are currently putting their efforts into creating technologically sophisticated solutions like a fully automated PCR swift test that can detect candida, with the intention of escalating diagnostic precision and improving the health outcomes of patients. A fully automated PCR quick test for detecting candida is a cutting-edge diagnostic instrument that utilises PCR technology to promptly and accurately determine the existence of Candida species in clinical samples. As an example, in May 2024, Bosch Healthcare Solutions GmbH, a medical technology manufacturing company based in Germany, introduced a PCR test for candida auris detection on the Vivalytic platform, providing fully automated, swift testing at the point of care within just an hour. This sophisticated test enables swift screenings and starkly contrasts with earlier culture methods that would take one to three days in centralized laboratories, thus postponing diagnosis and treatment. Specifically designed to be utilised in clinical settings, this test proves beneficial to high-risk patients as it allows for a timely diagnosis and combat against the severe health complications that C. auris infections often lead to.

Secure Your Global Candida Infection Testing Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report

Which Growth-Oriented Segments of the Candida Infection Testing Market Are Leading the Industry’s Development?

The candida infection testingmarket covered in this report is segmented –

1) By Type: Invasive Candidiasis, Candidemia

2) By Test Type: Vaginal pH Test, Nucleic Acid Amplification Testing (NAAT), Microbiome Test

3) By Application: Hospital, Laboratory

Subsegments:

1) By Invasive Candidiasis: Tissue Biopsy Testing, Urine Culture Testing, Blood Culture Testing

2) By Candidemia: Blood Tests, Serological Testing, Molecular Testing

What Regions Are Contributing Significantly to the Growth of the Candida Infection Testing Market?

North America was the largest region in the candida infection testing market in 2024. The regions covered in the candida infection testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Definition of the Candida Infection Testing Market Impacting Future Growth?

Candida infection testing refers to diagnostic procedures used to identify the presence of candida species, which are fungi that can cause infections in various parts of the body. These tests help determine the type and extent of the Candida infection, guiding appropriate treatment strategies.

Browse Through More Similar Reports By The Business Research Company:

Pseudomonas Aeruginosa Infection Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pseudomonas-aeruginosa-infection-treatment-global-market-report

High Level Disinfection Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/high-level-disinfection-services-global-market-report

Infection Control Supplies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: